Published in J Exp Med on July 21, 1997
Endothelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol (2009) 2.68
Cytokines in asthma. Thorax (1999) 2.64
T helper cell type 2 cytokine-mediated comitogenic responses and CCR3 expression during differentiation of human mast cells in vitro. J Exp Med (1999) 1.90
Eosinophils in innate immunity: an evolving story. Cell Tissue Res (2010) 1.34
Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders. Br J Pharmacol (2008) 1.25
Expression of ADAMs ("a disintegrin and metalloprotease") in the human lung. Virchows Arch (2009) 1.24
Stem cell factor-induced airway hyperreactivity in allergic and normal mice. Am J Pathol (1999) 0.99
Inhibition of stem cell factor reduces pulmonary cytokine levels during allergic airway responses. Clin Exp Immunol (2004) 0.94
Hypoxia modulates human eosinophil function. Clin Mol Allergy (2010) 0.88
Functional deregulation of KIT: link to mast cell proliferative diseases and other neoplasms. Immunol Allergy Clin North Am (2014) 0.86
Differential expression and biochemical activity of the immune receptor Tim-3 in healthy and malignant human myeloid cells. Oncotarget (2015) 0.86
FIP1L1/PDGFR alpha-associated systemic mastocytosis. Int Arch Allergy Immunol (2010) 0.82
Intranasal sirna targeting c-kit reduces airway inflammation in experimental allergic asthma. Int J Clin Exp Pathol (2014) 0.78
Eosinophil activation of fibroblasts from chronic allergen-induced disease utilizes stem cell factor for phenotypic changes. Am J Pathol (2007) 0.76
Platelet-driven leukotriene C4-mediated airway inflammation in mice is aspirin-sensitive and depends on T prostanoid receptors. J Immunol (2015) 0.75
Association of stem cell factor gene expression with severity and atopic state in patients with bronchial asthma. Respir Res (2017) 0.75
Effects of imatinib mesylate on pulmonary allergic vasculitis in a murine model. Int J Rheum Dis (2013) 0.75
Bidirectional Mast Cell-Eosinophil Interactions in Inflammatory Disorders and Cancer. Front Med (Lausanne) (2017) 0.75
VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell (1990) 8.87
Integrin-ligand binding properties govern cell migration speed through cell-substratum adhesiveness. Nature (1997) 8.52
Hereditary anemias of the mouse: a review for geneticists. Adv Genet (1979) 6.91
Molecular bases of dominant negative and loss of function mutations at the murine c-kit/white spotting locus: W37, Wv, W41 and W. EMBO J (1990) 5.08
Stem cell factor is encoded at the Sl locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell (1990) 5.06
Endothelial-leukocyte adhesion molecules. Annu Rev Immunol (1993) 4.96
Eotaxin: a potent eosinophil chemoattractant cytokine detected in a guinea pig model of allergic airways inflammation. J Exp Med (1994) 4.36
Molecular cloning of mast cell growth factor, a hematopoietin that is active in both membrane bound and soluble forms. Cell (1990) 3.98
Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils. J Clin Invest (1996) 3.74
Expression and function of c-kit in hemopoietic progenitor cells. J Exp Med (1991) 3.48
Lymphoid cells recognize an alternatively spliced segment of fibronectin via the integrin receptor alpha 4 beta 1. Cell (1990) 3.46
Hybrid cell lines secreting monoclonal antibody specific for major histocompatibility antigens of the mouse. Nature (1978) 3.45
An improved immunomagnetic procedure for the isolation of highly purified human blood eosinophils. J Immunol Methods (1991) 2.96
Mast cell growth factor maps near the steel locus on mouse chromosome 10 and is deleted in a number of steel alleles. Cell (1990) 2.95
Characterization of the cell surface heterodimer VLA-4 and related peptides. J Biol Chem (1987) 2.94
Suppression of integrin activation: a novel function of a Ras/Raf-initiated MAP kinase pathway. Cell (1997) 2.84
Adhesion of human basophils, eosinophils, and neutrophils to interleukin 1-activated human vascular endothelial cells: contributions of endothelial cell adhesion molecules. J Exp Med (1991) 2.76
Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am J Respir Cell Mol Biol (1994) 2.73
Cytotoxic effects of the guinea pig eosinophil major basic protein on tracheal epithelium. Lab Invest (1980) 2.70
Regulation of human eosinophil viability, density, and function by granulocyte/macrophage colony-stimulating factor in the presence of 3T3 fibroblasts. J Exp Med (1987) 2.69
Heterogeneity of mast cells and phenotypic change between subpopulations. Annu Rev Immunol (1989) 2.64
Induction of mast cell proliferation, maturation, and heparin synthesis by the rat c-kit ligand, stem cell factor. Proc Natl Acad Sci U S A (1991) 2.17
Characterization of a novel differentiation antigen complex recognize by a monoclonal antibody (A-1A5): unique activation-specific molecular forms on stimulated T cells. J Immunol (1983) 2.13
Expression and function of the MAdCAM-1 receptor, integrin alpha 4 beta 7, on human leukocytes. J Immunol (1994) 2.09
The pathophysiologic role of alpha 4 integrins in vivo. J Clin Invest (1994) 2.07
Trans-dominant inhibition of integrin function. Mol Biol Cell (1996) 1.92
Eosinophils express interleukin 5 and granulocyte macrophage-colony-stimulating factor mRNA at sites of allergic inflammation in asthmatics. J Clin Invest (1992) 1.81
Antibody-dependent cell-mediated damage to schistosomula in vitro. Nature (1974) 1.72
Identification of T lymphocytes, macrophages, and activated eosinophils in the bronchial mucosa in intrinsic asthma. Relationship to symptoms and bronchial responsiveness. Am Rev Respir Dis (1992) 1.68
Mechanisms of eosinophil recruitment. Am J Respir Cell Mol Biol (1993) 1.65
Lymphocyte activation antigens. I. A monoclonal antibody, anti-Act I, defines a new late lymphocyte activation antigen. J Immunol (1984) 1.60
Alpha 4-integrins mediate antigen-induced late bronchial responses and prolonged airway hyperresponsiveness in sheep. J Clin Invest (1994) 1.58
A monoclonal antibody recognizing very late activation antigen-4 inhibits eosinophil accumulation in vivo. J Exp Med (1993) 1.53
c-kit ligand: a unique potentiator of mediator release by human lung mast cells. J Exp Med (1992) 1.51
Synthesis and release of leukotriene C4 by human eosinophils. J Immunol (1987) 1.47
Mechanism of eosinophilia. V. Kinetics of normal and accelerated eosinopoiesis. Cell Tissue Kinet (1971) 1.42
Selective growth of human mast cells induced by Steel factor, IL-6, and prostaglandin E2 from cord blood mononuclear cells. J Immunol (1996) 1.38
Regulation of vascular cell adhesion molecule-1 expression by IL-4 and TNF-alpha in cultured endothelial cells. J Clin Invest (1995) 1.37
Constitutive expression of steel factor gene by human stromal cells. Blood (1993) 1.33
Development of human mast cells from umbilical cord blood cells by recombinant human and murine c-kit ligand. Proc Natl Acad Sci U S A (1993) 1.30
Stem cell factor induces mast cell adhesion to fibronectin. J Immunol (1994) 1.28
Strongyloides stercoralis: eosinophil-dependent immune-mediated killing of third stage larvae in BALB/cByJ mice. Exp Parasitol (1996) 1.27
Differential regulation of beta 1 and beta 2 integrin avidity by chemoattractants in eosinophils. Proc Natl Acad Sci U S A (1996) 1.26
Adhesion to fibronectin prolongs eosinophil survival. J Exp Med (1993) 1.25
Steel factor and c-kit regulate cell-matrix adhesion. Blood (1994) 1.24
Granulocyte/macrophage colony-stimulating factor (GM-CSF) gene expression by eosinophils in nasal polyposis. Am J Respir Cell Mol Biol (1991) 1.23
Antibody to very late activation antigen 4 prevents antigen-induced bronchial hyperreactivity and cellular infiltration in the guinea pig airways. J Exp Med (1994) 1.22
Soluble stem cell factor in human serum. Blood (1993) 1.21
Models for receptor-mediated cell phenomena: adhesion and migration. Annu Rev Biophys Biophys Chem (1991) 1.18
Peripheral lymphocyte and eosinophil counts as indicators of prognosis in primary breast cancer. Cancer (1983) 1.17
The eosinophil as a cellular source of transforming growth factor alpha in healing cutaneous wounds. Am J Pathol (1991) 1.15
Expression of endothelial and leukocyte adhesion molecules interacellular adhesion molecule-1, E-selectin, and vascular cell adhesion molecule-1 in the bronchial mucosa in steady-state and allergen-induced asthma. J Allergy Clin Immunol (1993) 1.14
Differentiation in vitro of hybrid eosinophil/basophil granulocytes: autocrine function of an eosinophil developmental intermediate. J Exp Med (1995) 1.14
Stem cell factor modulates avidity of alpha 4 beta 1 and alpha 5 beta 1 integrins expressed on hematopoietic cell lines. Blood (1995) 1.13
Sequential expression of transforming growth factors alpha and beta 1 by eosinophils during cutaneous wound healing in the hamster. Am J Pathol (1993) 1.08
Stem cell factor (c-kit ligand) influences eosinophil recruitment and histamine levels in allergic airway inflammation. J Immunol (1996) 1.08
IgE-dependent expression of mRNA for IL-4 and IL-5 in human lung mast cells. J Immunol (1995) 1.08
Second generation monoclonal antibodies to the human integrin alpha 6 beta 4. Hybridoma (1990) 1.07
Eosinophils are the major effector cells of immunity to microfilariae in a mouse model of onchocerciasis. Parasitology (1996) 1.04
Isolation and characterization of a monoclonal antibody that recognizes the human c-kit receptor. Blood (1992) 1.03
In situ expression of the cell adhesion molecules in bronchial tissues from asthmatics with air flow limitation: in vivo evidence of VCAM-1/VLA-4 interaction in selective eosinophil infiltration. Am J Respir Cell Mol Biol (1995) 0.98
Cell-mediated cytotoxicity to Trypanosoma cruzi. II. Antibody-dependent killing of bloodstream forms by mouse eosinophils and neutrophils. Am J Trop Med Hyg (1981) 0.98
Interleukin-3 regulates development of the 5-lipoxygenase/leukotriene C4 synthase pathway in mouse mast cells. J Biol Chem (1995) 0.96
Receptor tyrosine kinase stimulates cell-matrix adhesion by phosphatidylinositol 3 kinase and phospholipase C-gamma 1 pathways. Blood (1995) 0.95
Expression of a functional laminin receptor (alpha 6 beta 1, very late activation antigen-6) on human eosinophils. Blood (1993) 0.94
Ligation of CD69 induces apoptosis and cell death in human eosinophils cultured with granulocyte-macrophage colony-stimulating factor. Blood (1996) 0.89
In vitro anti-tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2. Role of interleukin 5. Int J Cancer (1993) 0.86
Infiltration of eosinophils in Hodgkin's disease involved lymph nodes predicts prognosis. Hematol Oncol (1994) 0.86
Synergistic action of interleukin-10 (IL-10) with IL-3, IL-4 and stem cell factor on colony formation from murine mast cells in culture. Int J Hematol (1995) 0.78
Intracellular single-chain antibody inhibits integrin VLA-4 maturation and function. Biochem J (1996) 0.77
High-yield preparation of isolated rat liver parenchymal cells: a biochemical and fine structural study. J Cell Biol (1969) 20.26
Cold urticaria: release into the circulation of histamine and eosinophil chemotactic factor of anaphylaxis during cold challenge. N Engl J Med (1976) 17.77
Large-scale analysis of the yeast genome by transposon tagging and gene disruption. Nature (1999) 9.87
Functions of coated vesicles during protein absorption in the rat vas deferens. J Cell Biol (1967) 7.79
Control of the amplification convertase of complement by the plasma protein beta1H. Proc Natl Acad Sci U S A (1976) 6.65
Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J Immunol (1982) 5.44
C3b inactivator of man. II. Fragments produced by C3b inactivator cleavage of cell-bound or fluid phase C3b. J Immunol (1971) 5.41
Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms. Proc Natl Acad Sci U S A (1977) 5.23
Variations in tight and gap junctions in mammalian tissues. J Cell Biol (1972) 5.08
Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res (2001) 4.87
Alternate complement pathway: factors involved in cobra venom factor (CoVF) activation of the third component of complement (C3). J Immunol (1973) 4.78
Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase. J Exp Med (1975) 4.69
C3 inactivator of man. I. Hemolytic measurement by the inactivation of cell-bound C3. J Immunol (1969) 4.38
An essential role in liver development for transcription factor XBP-1. Genes Dev (2000) 4.17
A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin. J Exp Med (1971) 4.07
Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med (1990) 4.06
Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function. N Engl J Med (1985) 4.00
A prealbumin activator of prekallikrein. 3. Appearance of chemotactic activity for human neutrophils by the conversion of human prekallikrein to kallikrein. J Exp Med (1972) 3.93
Formation of a hemolytically active cellular intermediate by the interaction between properdin factors B and D and the activated third component of complement. J Exp Med (1973) 3.83
A neutrophil-immobilizing factor derived from human leukocytes. I. Generation and partial characterization. J Exp Med (1972) 3.75
The IgE-mediated release of an eosinophil leukocyte chemotactic factor from human lung. J Immunol (1971) 3.51
Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1 H for cell-bound C3b. J Immunol (1979) 3.50
Immunological release of histamine and slow reacting substance of anaphylaxis from human lung. J Exp Med (1972) 3.31
Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor. Proc Natl Acad Sci U S A (1983) 3.30
The biologically active leukotrienes. Biosynthesis, metabolism, receptors, functions, and pharmacology. J Clin Invest (1984) 3.26
The stoichiometric measurement of the serum inhibition of the first component of complement by the inhibition of immune hemolysis. J Immunol (1968) 3.24
Properdin factor D: characterization of its active site and isolation of the precursor form. J Exp Med (1974) 3.21
A stoichiometric assay for the fourth component of complement in whole human serum using EAC'la-gp and functionally pure human second component. J Immunol (1967) 3.18
Local effects of synthetic leukotrienes (LTC4, LTD4, LTE4, and LTB4) in human skin. J Invest Dermatol (1983) 3.18
Slow reacting substances of anaphylaxis: identification of leukotrienes C-1 and D from human and rat sources. Proc Natl Acad Sci U S A (1980) 3.18
The complement system of man. I. N Engl J Med (1972) 3.09
Antibodies involved in antigen-induced release of slow reacting substance of anaphylaxis (SRS-A) in the guinea pig and rat. J Exp Med (1967) 3.08
A pre-albumin activator of prekallikrein. J Immunol (1970) 2.95
Comparative airway and vascular activities of leukotrienes C-1 and D in vivo and in vitro. Proc Natl Acad Sci U S A (1980) 2.94
Stimulation of human neutrophil leukocyte aerobic glucose metabolism by purified chemotactic factors. J Clin Invest (1974) 2.90
Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins. J Exp Med (1977) 2.87
Interleukin 3: A differentiation and growth factor for the mouse mast cell that contains chondroitin sulfate E proteoglycan. J Immunol (1984) 2.85
Native heparin from rat peritoneal mast cells. J Biol Chem (1977) 2.79
Inactivation of slow reacting substance of anaphylaxis by human eosinophil arylsulfatase. J Immunol (1975) 2.73
Regulation of human eosinophil viability, density, and function by granulocyte/macrophage colony-stimulating factor in the presence of 3T3 fibroblasts. J Exp Med (1987) 2.69
Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE. J Immunol (1982) 2.69
An eosinophil leukocyte chemotactic factor of anaphylaxis. J Exp Med (1971) 2.65
C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase. J Immunol (1976) 2.64
Purification and synthesis of eosinophilotactic tetrapeptides of human lung tissue: identification as eosinophil chemotactic factor of anaphylaxis. Proc Natl Acad Sci U S A (1975) 2.56
Immunological release of histamine and slow reacting substance of anaphylaxis from human lung. II. Influence of cellular levels of cyclic AMP. Fed Proc (1972) 2.55
The complement system in rheumatoid synovitis. I. An analysis of complement component activities in rheumatoid synovial fluids. Arthritis Rheum (1971) 2.53
Identification of the C(6)-S-conjugate of leukotriene A with cysteine as a naturally occurring slow reacting substance of anaphylaxis (SRS-A). Importance of the 11-cis-geometry for biological activity. Biochem Biophys Res Commun (1980) 2.49
Mediation of local homeostasis and inflammation by leukotrienes and other mast cell-dependent compounds. Nature (1981) 2.41
Immunological release of histamine and slow-reacting substance of anaphylaxis from human lung. I. Modulation by agents influencing cellular levels of cyclic 3',5'-adenosine monophosphate. J Exp Med (1971) 2.39
Tryptase from human pulmonary mast cells. Purification and characterization. J Biol Chem (1981) 2.37
The physicochemical characteristics and purification of slow-reacting substance of anaphylaxis. J Immunol (1973) 2.34
Heparin is essential for the storage of specific granule proteases in mast cells. Nature (1999) 2.34
Metabolism of third complement component (C3) in nephritis. Involvement of the classic and alternate (properdin) pathways for complement activation. N Engl J Med (1972) 2.33
Hereditary deficiency of the second component of complement (C'2) in man. J Clin Invest (1966) 2.32
The fibrinolytic pathway of human plasma. Isolation and characterization of the plasminogen proactivator. J Exp Med (1972) 2.31
Enhancement of human eosinophil cytotoxicity and leukotriene synthesis by biosynthetic (recombinant) granulocyte-macrophage colony-stimulating factor. J Immunol (1986) 2.31
Tumor-associated eosinophilotactic factor. N Engl J Med (1974) 2.27
Slow reacting substance of anaphylaxis. Adv Immunol (1969) 2.23
Properdin: initiation of alternative complement pathway. Proc Natl Acad Sci U S A (1975) 2.20
Inactivation of slow reacting substance of anaphylaxins (SRS-A) by arylsulfatases. J Immunol (1974) 2.19
Properdin factor D. II. Activation to D by properdin. J Exp Med (1974) 2.19
Hereditary deficiency of the second component of complement (C2) in man: correlation of C2 haemolytic activity with immunochemical measurements of C2 protein. Immunology (1970) 2.17
Effects of intravenous administration of slow-reacting substance of anaphylaxis, histamine, bradykinin, and prostaglandin F2alpha on pulmonary mechanics in the guinea pig. J Clin Invest (1974) 2.16
Cyclic AMP, ATP, and reversed anaphylactic histamine release from rat mast cells. J Immunol (1974) 2.16
Human eosinophils have prolonged survival, enhanced functional properties, and become hypodense when exposed to human interleukin 3. J Clin Invest (1988) 2.15
Culture from mouse bone marrow of a subclass of mast cells possessing a distinct chondroitin sulfate proteoglycan with glycosaminoglycans rich in N-acetylgalactosamine-4,6-disulfate. J Biol Chem (1982) 2.13
Interaction of plasma kallikrein with the C1 inhibitor. J Immunol (1970) 2.07
Current concepts in immunology: the alternative pathway of complement--a system for host resistance to microbial infection. N Engl J Med (1980) 2.07
Leukotriene B4 action on endothelium mediates augmented neutrophil/endothelial adhesion. Proc Natl Acad Sci U S A (1984) 2.06
Immunologic release of beta-hexosaminidase and beta-glucuronidase from purified rat serosal mast cells. J Immunol (1979) 2.01
Coculture of interleukin 3-dependent mouse mast cells with fibroblasts results in a phenotypic change of the mast cells. Proc Natl Acad Sci U S A (1986) 2.00
A beta-glucan inhibitable receptor on human monocytes: its identity with the phagocytic receptor for particulate activators of the alternative complement pathway. J Immunol (1985) 2.00
Hereditary deficiency of the second component of complement (C'2) in man: further observations on a second kindred. J Immunol (1967) 1.98
Eotaxin is required for the baseline level of tissue eosinophils. Proc Natl Acad Sci U S A (1998) 1.98
Interleukin 5 and phenotypically altered eosinophils in the blood of patients with the idiopathic hypereosinophilic syndrome. J Exp Med (1989) 1.97
The permeability barrier in mammalian epidermis. J Cell Biol (1975) 1.94
Initiation of C3 cleavage in the alternative complement pathway. J Immunol (1975) 1.94
Sorting out the cytokines of asthma. J Exp Med (1996) 1.92
The release of four mediators of immediate hypersensitivity from human leukemic basophils. J Immunol (1975) 1.92
The modulating influence of cyclic nucleotides upon lymphocyte-mediated cytotoxicity. J Exp Med (1973) 1.92
Generation and metabolism of 5-lipoxygenase pathway leukotrienes by human eosinophils: predominant production of leukotriene C4. Proc Natl Acad Sci U S A (1983) 1.91
Bronchoconstrictor effects of leukotriene C in humans. Science (1982) 1.91
Structural polymorphism of the fourth component of human complement. J Clin Invest (1969) 1.91
Freeze-fracture identification of sterol-digitonin complexes in cell and liposome membranes. J Cell Biol (1978) 1.90
T helper cell type 2 cytokine-mediated comitogenic responses and CCR3 expression during differentiation of human mast cells in vitro. J Exp Med (1999) 1.90
Cytochemical staining of multivesicular body and golgi vesicles. J Cell Biol (1969) 1.88
Proton-induced fusion of oleic acid-phosphatidylethanolamine liposomes. Biochemistry (1985) 1.88
Assembly of gap junctions during amphibian neurulation. J Cell Biol (1974) 1.88
The serum bactericidal reaction. 3. Antibody and complement requirements for killing a rough Escherichia coli. J Immunol (1969) 1.87
Immunochemical and biologic properties of rat IgE. I. Immunochemical identification of rat IgE. J Immunol (1970) 1.83
Mast cells that reside at different locations in the jejunum of mice infected with Trichinella spiralis exhibit sequential changes in their granule ultrastructure and chymase phenotype. J Cell Biol (1996) 1.83
Role of adenylate cyclase in immunologic release of mediators from rat mast cells: agonist and antagonist effects of purine- and ribose-modified adenosine analogs. Proc Natl Acad Sci U S A (1980) 1.82
Enhancement of random migration and chemotactic response of human leukocytes by ascorbic acid. J Clin Invest (1974) 1.81
Surface membrane expression by human blood leukocytes and platelets of decay-accelerating factor, a regulatory protein of the complement system. Blood (1985) 1.79
Expression cloning of a cDNA for human leukotriene C4 synthase, an integral membrane protein conjugating reduced glutathione to leukotriene A4. Proc Natl Acad Sci U S A (1994) 1.79
Complement in human disease. Annu Rev Med (1968) 1.79
A radioimmunoassay for bradykinin in plasma and synovial fluid. J Lab Clin Med (1969) 1.79